ATE450514T1 - Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung - Google Patents

Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung

Info

Publication number
ATE450514T1
ATE450514T1 AT06254404T AT06254404T ATE450514T1 AT E450514 T1 ATE450514 T1 AT E450514T1 AT 06254404 T AT06254404 T AT 06254404T AT 06254404 T AT06254404 T AT 06254404T AT E450514 T1 ATE450514 T1 AT E450514T1
Authority
AT
Austria
Prior art keywords
piperazinylalkylpyrazole
derivatives
calcium channel
production
channel blockers
Prior art date
Application number
AT06254404T
Other languages
English (en)
Inventor
Ghil-Soo Nam
Kyung-Il Choi
Hun-Yeong Koh
Ae-Nim Pae
Hye-Whon Rhim
In-Sung Choi
Original Assignee
Korea Inst Sci & Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Inst Sci & Tech filed Critical Korea Inst Sci & Tech
Application granted granted Critical
Publication of ATE450514T1 publication Critical patent/ATE450514T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06254404T 2005-08-26 2006-08-22 Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung ATE450514T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020050079095A KR100654328B1 (ko) 2005-08-26 2005-08-26 피페라지닐알킬피라졸계 ｔ-타입 칼슘 채널 억제 화합물 및이의 제조방법

Publications (1)

Publication Number Publication Date
ATE450514T1 true ATE450514T1 (de) 2009-12-15

Family

ID=37529291

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06254404T ATE450514T1 (de) 2005-08-26 2006-08-22 Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung

Country Status (5)

Country Link
US (1) US7544686B2 (de)
EP (1) EP1757590B1 (de)
KR (1) KR100654328B1 (de)
AT (1) ATE450514T1 (de)
DE (1) DE602006010776D1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100882925B1 (ko) * 2007-06-14 2009-02-10 한국과학기술연구원 세로토닌 5-ｈｔ₃ａ 길항적 효과를 갖는 피라졸 유도체함유 약제 조성물
KR101014887B1 (ko) 2008-06-26 2011-02-15 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 이미다졸릴알킬카르보닐유도체 및 그의 제조방법
KR101052065B1 (ko) 2008-10-15 2011-07-27 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법
JP5722891B2 (ja) 2010-07-15 2015-05-27 大日本住友製薬株式会社 ピラゾール化合物
EP2671582B1 (de) 2011-02-01 2016-07-13 Kyowa Hakko Kirin Co., Ltd. Kondensierte heterocyclische derivate
EP2881394B1 (de) 2012-07-31 2018-03-21 Kyowa Hakko Kirin Co., Ltd. Kondensierte heterocyclische ringverbindung
KR20160074540A (ko) 2013-10-17 2016-06-28 다우 아그로사이언시즈 엘엘씨 살충성 화합물의 제조 방법
CA2925953C (en) 2013-10-17 2021-11-02 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
CN105636444B (zh) 2013-10-17 2018-04-27 美国陶氏益农公司 制备杀虫化合物的方法
CN105636440A (zh) 2013-10-17 2016-06-01 美国陶氏益农公司 制备杀虫化合物的方法
MX2016004942A (es) * 2013-10-17 2016-06-28 Dow Agrosciences Llc Procesos para la preparacion de compuestos plaguicidas.
KR20160074542A (ko) 2013-10-17 2016-06-28 다우 아그로사이언시즈 엘엘씨 살충성 화합물의 제조 방법
EP3057431A4 (de) 2013-10-17 2017-04-05 Dow AgroSciences LLC Verfahren zur herstellung von pestizidverbindungen
HUE040489T2 (hu) * 2014-06-03 2019-03-28 Idorsia Pharmaceuticals Ltd Pirazolvegyületek és alkalmazásuk t-típusú kalciumcsatorna-blokkolókként
US9029556B1 (en) 2014-07-31 2015-05-12 Dow Argosciences Llc Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
CA2954631A1 (en) 2014-07-31 2016-02-04 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
EP3174856A4 (de) 2014-07-31 2018-01-10 Dow AgroSciences LLC Verfahren zur herstellung von 3(-3-chlor-1h-pyrazol-1-yl)pyridin
WO2016028328A1 (en) 2014-08-19 2016-02-25 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
KR20170058388A (ko) 2014-09-12 2017-05-26 다우 아그로사이언시즈 엘엘씨 3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법
JP6957460B2 (ja) 2015-10-22 2021-11-02 カビオン・インコーポレイテッドＣａｖｉｏｎ， Ｉｎｃ． アンジェルマン症候群および関連する障害の処置方法
CN110139853B (zh) 2016-12-29 2023-06-16 美国陶氏益农公司 用于制备杀有害生物化合物的方法
WO2018125817A1 (en) 2016-12-29 2018-07-05 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
JP7134178B2 (ja) 2017-02-15 2022-09-09 カビオン・インコーポレイテッド カルシウムチャネル阻害剤
MX2019012818A (es) 2017-04-26 2020-07-14 Cavion Inc Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
TW202027728A (zh) 2018-10-03 2020-08-01 美商卡凡恩公司 以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫
WO2021007487A1 (en) 2019-07-11 2021-01-14 Praxis Precision Medicines, Inc. Formulations of t-type calcium channel modulators and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032526A (en) 1975-10-02 1977-06-28 American Cyanamid Company 1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts
CA1279645C (en) 1986-02-27 1991-01-29 Ineke Van Wijngaarden Aryl-substituted (n-piperidinyl)methyl- and (n-piperazinyl)methylazoles having antipsychotic properties
FR2672052B1 (fr) * 1991-01-28 1995-05-24 Esteve Labor Dr Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
JPH09227524A (ja) * 1996-02-29 1997-09-02 Taisho Pharmaceut Co Ltd フェニルピラゾール誘導体
US5808088A (en) 1997-04-30 1998-09-15 Roche Colorado Corporation Preparation of mibefradil via an acetamide anion

Also Published As

Publication number Publication date
US7544686B2 (en) 2009-06-09
KR100654328B1 (ko) 2006-12-08
EP1757590B1 (de) 2009-12-02
DE602006010776D1 (de) 2010-01-14
US20070049604A1 (en) 2007-03-01
EP1757590A1 (de) 2007-02-28

Similar Documents

Publication Publication Date Title
ATE450514T1 (de) Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung
TW200517109A (en) Substituted pyridinones
AP1822A (en) Substituted pyridinones as modulators of P38 MAP kinase.
HK1119699A1 (en) Pyridopyrimidinone inhibitors of pi3kalpha
WO2009063202A3 (en) Use of crth2 antagonist compounds
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
EP1627635A3 (de) Benzothiazolium Verbindungen zur Verwendung in Methoden zur Hemmung der NO Produktion und von TNF alpha und zur Behandlung von Coronavirus Infektionen
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
WO2005013892A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
ATE464308T1 (de) Stereoisomere verbindungen und verfahren zur behandlung von erkrankungen des magen-darm-trakts und des zentralen nervensystems
HK1094421A1 (en) (S)-2-n-propylamino-5-hydroxytetralin as a d3-agonist
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
NO20082096L (no) Azaindol-2-karboksamidderivativer
MY147404A (en) Process for preparation of n-benzoyl-staurosporine
TW200637860A (en) Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
NO20052699L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
DE60311869D1 (de) Kristalline cefdinirsalze
DE602004021358D1 (de) Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
UA86873C2 (en) SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
DE602004019778D1 (de) Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen
ATE485820T1 (de) Verwendung von n-(dibenz (b,f)oxepin-10-ylmethyl)-n-methyl-n-prop-2-inyl min (omigapil) zur prophylaxe und/oder behandlung von muskeldystrophie
HK1080768A1 (en) Use of epothilone derivatives for the treatment ofhyperparathyroidism

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties